Thelansis

Endometrial carcinoma is a cancer that affects the lining of the uterus (endometrium) in younger women. It is estrogen-dependent and characterized by a defined precursor lesion called endometrial intraepithelial neoplasia (EIN). The pathogenesis is believed to begin with uninterrupted endometrial proliferation stimulated by estrogen, which progresses through various stages of endometrial hyperplasia. Lead to the development of EIN, which can transform into endometrioid carcinoma. It can be characterized by stromal and myometrial invasion, mutations in certain genes (PTEN and KRAS2), microsatellite instability caused by mismatch repair defects, and a near-diploid karyotype. The tumor also usually expresses estrogen and progesterone receptors (ER and PR). The natural history of endometrial carcinomas is that they begin as preinvasive intraepithelial lesions, which then progress to invasive cancers involving the endometrial stroma and then penetrating deeper into the myometrium. Lead to t...

 Endometrial carcinoma, also called Endometrial cancer ,  starts in the cells of the inner lining of the uterus (the endometrium). It is the most common type of uterus cancer. Thelansis’s “Endometrial Carcinoma Market Outlook, Epidemiology, Competitive Landscape , and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Endometrial Carcinoma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). KOLs insights of Endometrial Carcinoma across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs. Endometrial Carcinoma Market ...